

Program ramowy / Overview of scientific program

Victoria Hotel, 58-60 Narutowicza Street, Lublin, Poland

Thursday, 23 November 2017

13.00 – 14.30

Session 1. Diagnostic tools for evaluation of peritoneal metastases

15.00 – 16.30

Session 2. Cytological & molecular evaluation of peritoneal fluid

17.00 – 18.30

Session 3. Evidence behind cytoreductive surgery & hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies

Friday, 24 November 2017

8.30 – 9.00

Special lecture: G. Johan A. Offerhaus (Utrecht, the Netherlands)
What molecular sub-types of gastric cancer have potential for peritoneal dissemination?

9.00 – 10.30

Session 4. Comprehensive treatment of peritoneal metastases from gastric carcinoma

11.00 – 13.00

Session 5. Prophylactic/proactive intraperitoneal treatment of gastric carcinoma

Lunch

14.00 – 15.30

Session 6. Ovarian metastases from gastro-intestinal carcinomas: Krukenberg tumours

16.00 – 17.30

Session 7. Innovations & future of intraperitoneal treatment

Program naukowy / Scientific program

Thursday, 23 November 2017

13.00 – 14.30

Session 1. Diagnostic tools for evaluation of peritoneal metastases

Chair: Dawid Murawa (Gniezno/Zielona Góra), Tomasz Skoczylas (Lublin), Wojciech Polkowski (Lublin)

1. Laparoscopy – Wojciech Zegarski (Bydgoszcz)
2. CT manifestation of peritoneal metastases – Joanna Kruk-Bachonko (Lublin)
3. Diagnosis of peritoneal carcinomatosis in 18FDG PET/CT – Beata Chrapko (Lublin)

Discussion

15.00 – 16.30

Session 2. Cytological & molecular evaluation of peritoneal fluid

Chair: Daniele Marrelli (Siena, Italy), Wojciech Zegarski (Bydgoszcz), Jacek M. Witkowski (Gdańsk)

1. Training of young surgeons in CRS and HIPEC – Karol Połom (Siena, Italy)
2. Mechanisms of cancer metastasis to the peritoneum – Jacek M. Witkowski (Gdańsk)
3. The novel and innovative solutions for HIPEC and CRS - where we are and where we are going? – Maciej S. Nowacki (Bydgoszcz)

Discussion

17.00 – 18.30

Session 3. Evidence behind cytoreductive surgery & hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies

Chair: Santiago Gonzalez-Moreno (Madrid, Spain), Tomasz Jastrzębski (Gdańsk), Dawid Murawa (Gniezno/Zielona Góra)

1. Pseudomyxoma & Mesothelioma – Santiago Gonzalez-Moreno (Madrid, Spain)
2. Significance of primary tumour removal (cytoreduction) in metastatic Colorectal carcinoma – Lucjan Wyrwicz (Warszawa)
3. The role of HIPEC for recurrent ovarian cancer – Łukasz Wicherek (Bydgoszcz)

Discussion

Friday, 24 November 2017

8.30 – 9.00

Special lecture

What molecular sub-types of gastric cancer have potential for peritoneal dissemination? - G. Johan A. Offerhaus (Utrecht, the Netherlands)

9.00 – 10.30

Session 4. Comprehensive treatment of peritoneal metastases from gastric carcinoma

Chair: Piotr Richter (Kraków), Olivier Glehen (Lyon, France), Santiago Gonzalez-Moreno (Madrid, Spain)

1. Which patient is going to benefit from surgical cytoreduction with intraperitoneal chemotherapy (for manifest peritoneal metastases) – Pompiliu Piso (Regensburg, Germany)
2. Does additional HIPEC helps after CRS in peritoneal disseminated gastric cancer? – Beate Rau (Berlin, Germany)
3. Conversion therapy in patients with peritoneal carcinomatosis from gastric cancer – Daniele Marrelli (Siena, Italy)

Discussion

11.00 – 13.00

Session 5. Prophylactic/proactive intraperitoneal treatment of gastric carcinoma

Chair: Pompiliu Piso (Regensburg, Germany), Beate Rau (Berlin, Germany), Wojciech Polkowski (Lublin)

1. Clinical significance of cytological status of peritoneal lavage fluid in gastric cancer without overt peritoneal dissemination – Dawid Murawa (Gniezno/Zielona Góra)
2. GastriCHIP Trial: prophylactic HIPEC in gastric cancer – Olivier Glehen (Lyon, France)
3. Molecular classifications of gastric cancer as new tools for identification of patients at risk of peritoneal carcinomatosis – Daniele Marrelli (Siena, Italy)
4. HIPEC in combined treatment of locally advanced and intraperitoneally disseminated gastric cancer: Lviv results – Roman Yarema (Lviv, Ukraine)

Discussion

LUNCH

14.00 – 15.30

Session 6. Ovarian metastases from gastro-intestinal carcinomas: Krukenberg tumours

Chair: Beate Rau (Berlin, Germany), Łukasz Wicherek (Bydgoszcz), Lucjan Wyrwicz (Warszawa)

1. Systemic treatment – Sławomir Mandziuk (Lublin)
 2. Cytoreductive surgery and HIPEC in ovarian cancer treatment: the Bydgoszcz Oncological Center experience – Łukasz Wicherek (Bydgoszcz)
 3. Surgical treatment of gastric carcinoma with ovarian metastases – Tomasz Olesiński (Warszawa)
- Discussion

16.00 – 17.30

Session 7. Innovations & future of intraperitoneal treatment

Chair: Santiago Gonzalez-Moreno (Madrid, Spain), Tomasz Jastrzębski (Gdańsk), Olivier Glehen (Lyon, France)

1. “Second look” laparotomy: for whom and for what ? – Olivier Glehen (Lyon, France)
 2. HIPEC as an preventive treatment of colon cancer – Tomasz Jastrzębski (Gdańsk)
 3. (Neo)Adjuvant laparoscopic HIPEC or PIPAC – do we have enough data to support the routine use? Pompiliu Piso (Regensburg, Germany)
- Discussion